(("clinical guidelines"[Resource Type]) OR "practice guideline"[Public - Books

Result Filters

Results: 8 books (9 items)

Quoted phrase not found.
See the search details.

Select item 48890041.

Addendum to Haematological Cancers: improving outcomes (update).

National Collaborating Centre for Cancer (UK).

London: National Institute for Health and Care Excellence (NICE); 2016 May.

Top results in this book Table of Contents

Select item 40828742.

Manual on Paediatric HIV Care and Treatment for District Hospitals: Addendum to the Pocket Book of Hospital Care of Children.

Geneva: World Health Organization; 2011.

Top results in this book Table of Contents

Select item 53410763.

WHO guideline for the treatment of visceral leishmaniasis in HIV co-infected patients in East Africa and South-East Asia [Internet].

Geneva: World Health Organization; 2022.

Top results in this book Table of Contents

Select item 55022984.

$Isatuximab (Sarclisa): CADTH Reimbursement Recommendation: Indication: In combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy [Internet].$

Isatuximab (Sarclisa): CADTH Reimbursement Recommendation: Indication: In combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Feb.

Top results in this book Table of Contents

Select item 56350285.

$Teclistamab (Tecvayli): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].$

Teclistamab (Tecvayli): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Apr.

Top results in this book Table of Contents

Select item 41024846.

Anthrax in Humans and Animals. 4th edition.

Geneva: World Health Organization; 2008.

Top results in this book Table of Contents

Select item 52097647.

WHO guidelines for plague management: revised recommendations for the use of rapid diagnostic tests, fluoroquinolones for case management and personal protective equipment for prevention of post-mortem transmission [Internet].

Geneva: World Health Organization; 2021.

Top results in this book Table of Contents

Select item 56500208.

$Elranatamab (Elrexfio): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy [Internet].$